Semaglutide vs. Tirzepatide vs. Retatrutide: What Actually Makes Them Different?

Few areas of metabolic research have moved as quickly as incretin-based therapies.

Semaglutide changed expectations for what pharmacological weight management could accomplish. Tirzepatide subsequently introduced a second hormonal target and produced still greater average weight reductions in clinical trials. Now retatrutide is being studied as a triple-receptor agonist targeting GLP-1, GIP and glucagon receptors.

The three compounds are frequently grouped together under the informal label “GLP-1s,” but scientifically, that description misses an important distinction:

They do not activate the same receptors.

Understanding that difference helps explain why researchers are so interested in the progression from semaglutide to tirzepatide to retatrutide.

The simplest way to understand the three

Semaglutide: GLP-1

Tirzepatide: GIP + GLP-1

Retatrutide: GIP + GLP-1 + glucagon

Semaglutide is a GLP-1 receptor agonist.

Tirzepatide is a dual GIP/GLP-1 receptor agonist.

Retatrutide is an investigational GIP/GLP-1/glucagon triple-receptor agonist.

That additional glucagon-receptor activity is one of the characteristics that makes retatrutide particularly interesting from a metabolic-research perspective.

Semaglutide: targeting GLP-1

GLP-1, or glucagon-like peptide-1, is a naturally occurring hormone involved in appetite, digestion and glucose regulation.

Activating the GLP-1 receptor can influence several physiological processes, including satiety and food intake. GLP-1 receptor agonists also slow gastrointestinal transit and influence insulin and glucagon responses to food.

Semaglutide therefore primarily approaches metabolic regulation through one hormonal receptor system: GLP-1.

Its effectiveness was demonstrated prominently in the STEP 1 clinical trial involving 1,961 adults with overweight or obesity without diabetes.

After 68 weeks, participants receiving semaglutide 2.4 mg plus lifestyle intervention experienced substantial average reductions in body weight compared with placebo.

The results helped establish GLP-1 receptor agonism as a major therapeutic approach to obesity research.

Tirzepatide: adding GIP

Tirzepatide expanded the concept by activating two receptors:

GIP + GLP-1

GIP stands for glucose-dependent insulinotropic polypeptide.

Like GLP-1, GIP is an incretin hormone released in response to nutrients. It participates in glucose regulation and insulin secretion, although its biology extends beyond those functions.

Instead of relying entirely on GLP-1 receptor activity, tirzepatide combines activity at the GIP and GLP-1 receptors within the same molecule.

The SURMOUNT-1 trial demonstrated the significance of this approach.

More than 2,500 adults with obesity or overweight without diabetes participated in the 72-week randomized trial.

At the highest studied dose, average weight reduction exceeded 20% in the trial's efficacy analysis.

That was an important development because pharmacological weight reduction was beginning to approach levels that previously had been difficult to achieve without bariatric procedures.

Tirzepatide is now FDA approved for chronic weight management under the brand name Zepbound and for type 2 diabetes under the brand name Mounjaro.

Retatrutide: adding a third receptor

Retatrutide takes the multi-receptor concept another step.

It activates:

GIP + GLP-1 + glucagon

The third component—glucagon-receptor agonism—is what makes retatrutide fundamentally different from semaglutide and tirzepatide.

Glucagon is commonly associated with raising blood glucose, which can initially make its inclusion in an obesity drug seem counterintuitive.

But glucagon signaling also participates in broader energy metabolism.

Researchers have therefore investigated whether carefully balancing glucagon activity with GLP-1 and GIP receptor activation could influence both energy intake and energy expenditure.

This creates an intriguing research hypothesis.

Rather than approaching body-weight regulation predominantly from the food-intake side of the energy-balance equation, a triple agonist may potentially influence multiple components of metabolism simultaneously.

That does not mean retatrutide simply “burns fat,” as it is sometimes described online. Human metabolism is substantially more complicated.

But the addition of glucagon-receptor activity represents a meaningful biological difference.

What have retatrutide trials found?

Early enthusiasm surrounding retatrutide largely came from a Phase 2 randomized trial published in The New England Journal of Medicine in 2023.

Participants receiving the highest studied dose experienced an average weight reduction of approximately 24% at 48 weeks.

Researchers also noted something unusual:

Weight-loss curves at the highest doses had not clearly plateaued by the end of the 48-week study.

That raised an obvious question:

What happens when retatrutide is studied for substantially longer?

We now have part of the answer.

Phase 3 changed the picture in 2026

In May 2026, Eli Lilly announced topline results from the Phase 3 TRIUMPH-1 trial.

Among participants without diabetes, mean body-weight reductions at 80 weeks were reported as:

4 mg: 19.0%

9 mg: 25.9%

12 mg: 28.3%

Among participants receiving 12 mg, 45.3% achieved at least 30% body-weight reduction in the efficacy analysis.

A prespecified extension followed participants with a starting BMI of at least 35 for 104 weeks. Participants continuing on the 12 mg arm reached an average 30.3% reduction from baseline in the efficacy analysis.

Additional Phase 3 results announced in July 2026 showed substantial reductions in populations with type 2 diabetes and established cardiovascular disease as well.

These are company-reported topline Phase 3 results. Full peer-reviewed publication of the newer datasets remains important for evaluating the findings in greater detail.

Does that mean retatrutide is simply “stronger”?

This is where online discussions frequently oversimplify the science.

It is tempting to arrange the compounds like this:

Semaglutide → Tirzepatide → Retatrutide

and interpret that as:

Good → Better → Best.

Clinical research does not work quite that cleanly.

The headline percentages come from different trials involving different participants, protocols, treatment durations and statistical analyses.

A 68-week semaglutide trial cannot simply be placed beside an 80-week retatrutide trial and treated as a head-to-head competition.

Direct comparative trials provide much stronger evidence for determining relative effects than comparing headline numbers from unrelated studies.

The more scientifically useful conclusion is:

The compounds target progressively different combinations of metabolic receptors, and clinical research suggests those differences can produce meaningfully different physiological effects.

Why does glucagon matter so much?

This may ultimately be one of the most interesting questions surrounding retatrutide.

Weight change is governed by energy balance over time.

Very simplistically:

Energy consumed – energy expended = stored or lost energy

GLP-1-based therapies can substantially influence the intake side of that equation by altering appetite and satiety.

Researchers studying glucagon-containing multi-agonists are interested in whether glucagon signaling can also influence energy expenditure and substrate metabolism.

Preclinical and mechanistic research supports that possibility.

But translating receptor biology into real-world human outcomes is complicated. Researchers still need to determine exactly how much of retatrutide's observed effect comes from appetite reduction, altered energy expenditure, metabolic signaling, or interactions among all three receptor systems.

That is a far more interesting scientific question than simply calling retatrutide a “stronger GLP-1.”

What about appetite?

Another misconception is that greater weight reduction must mean greater appetite suppression.

Not necessarily.

GLP-1 signaling is strongly associated with satiety and reduced food intake, but retatrutide's pharmacology involves three receptor systems.

That means subjective hunger alone may not tell the entire story.

Two compounds could theoretically produce different body-weight outcomes even if people describe similar—or potentially different—levels of appetite suppression.

Anecdotal reports about one compound suppressing appetite more than another are interesting observations, but they cannot establish which compound produces a greater metabolic effect.

What about muscle and lean mass?

This is becoming one of the most important questions in obesity pharmacology.

Significant weight loss generally involves losses of both fat mass and lean mass.

That phenomenon is not unique to GLP-1 medications.

When substantial weight is lost—whether through caloric restriction, medication or bariatric surgery—some reduction in lean tissue commonly accompanies the reduction in fat mass.

Researchers are therefore increasingly interested not simply in how much weight is lost, but in what type of tissue accounts for that loss.

Resistance training, adequate dietary protein and overall nutritional status are consequently important areas of investigation alongside pharmacological obesity treatment.

This subject deserves its own article because “30 pounds lost” and “30 pounds of fat lost” are not biologically equivalent statements.

Side effects are part of the comparison too

Greater biological activity does not automatically mean a compound is preferable.

Gastrointestinal adverse effects are common across incretin-based therapies.

Frequently reported effects include nausea, diarrhea, constipation, vomiting and abdominal discomfort.

In TRIUMPH-1, gastrointestinal events were among the most commonly reported adverse events with retatrutide, and their frequency generally increased at higher doses.

For example, nausea was reported in 28.6%, 38.4% and 42.4% of participants in the 4 mg, 9 mg and 12 mg groups respectively, compared with 14.8% with placebo.

This illustrates an important principle in pharmacology:

Efficacy cannot be separated from tolerability and safety.

Their regulatory status is also very different

As of September 2026:

Semaglutide is FDA approved for several indications. Wegovy is approved for chronic weight management in appropriate patients, among other indications.

Tirzepatide is FDA approved. Zepbound is approved for chronic weight management in appropriate adults, while Mounjaro is approved for type 2 diabetes.

Retatrutide is not FDA approved.

It remains an investigational drug.

Eli Lilly has stated that its Phase 3 clinical-data package will support planned regulatory submissions and that it intends to submit retatrutide to the FDA in the first quarter of 2027.

That distinction is critical when discussing these compounds.

Published research about an investigational molecule should not be confused with regulatory approval.

So what actually separates the three?

The most useful distinction isn't simply how much weight participants lost in individual studies.

It is their underlying pharmacology.

Semaglutide — one receptor: GLP-1

Tirzepatide — two receptors: GIP + GLP-1

Retatrutide — three receptors: GIP + GLP-1 + glucagon

The evolution from single to dual to triple agonism represents a broader shift occurring in metabolic research.

Instead of targeting one biological pathway at a time, researchers are increasingly investigating molecules capable of coordinating multiple hormonal systems simultaneously.

Whether triple agonism ultimately represents the next major step in obesity treatment will depend on more than weight-loss percentages.

Long-term safety, tolerability, cardiovascular outcomes, metabolic effects, body composition, durability of weight loss and regulatory review will all matter.

But the scientific idea behind retatrutide is much more interesting than simply creating another “GLP-1.”

It represents an attempt to influence multiple sides of human energy regulation with one molecule.

And that may be the most important difference of all.